Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 425-020-0 | CAS number: 191680-81-6 CGL 116
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 022
- Report date:
- 2022
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Version / remarks:
- 25 June 2018
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
Test material
- Reference substance name:
- Reaction products of N,N'-ethane-1,2-diylbis(1,3-propanediamine), cyclohexane, peroxidized 4-butylamino-2,2,6,6-tetramethylpiperidine and 2,4,6-trichloro-1,3,5-triazine
- EC Number:
- 425-020-0
- EC Name:
- Reaction products of N,N'-ethane-1,2-diylbis(1,3-propanediamine), cyclohexane, peroxidized 4-butylamino-2,2,6,6-tetramethylpiperidine and 2,4,6-trichloro-1,3,5-triazine
- Cas Number:
- 191680-81-6
- Molecular formula:
- C50H77N11O2-C168H230N32O8
- IUPAC Name:
- N2-(2-{[4,6-bis({butyl[1-(cyclohexyloxy)-2,2,6,6-tetramethylpiperidin-4-yl]amino})-1,3,5-triazin-2-yl](3-{[4,6-bis({butyl[1-(cyclohexyloxy)-2,2,6,6-tetramethylpiperidin-4-yl]amino})-1,3,5-triazin-2-yl]amino}propyl)amino}ethyl)-N2-(3-{[4,6-bis({butyl[1-(cyclohexyloxy)-2,2,6,6-tetramethylpiperidin-4-yl]amino})-1,3,5-triazin-2-yl]amino}propyl)-N4,N6-dibutyl-N4,N6-bis[1-(cyclohexyloxy)-2,2,6,6-tetramethylpiperidin-4-yl]-1,3,5-triazine-2,4,6-triamine
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: ordered from Charles River Italia S.p.A., Calco (Lecco), Italy and supplied by Charles River Laboratories, France.
- Age at study initiation: 9 weeks (females), 11 weeks (males)
- Weight at study initiation: 200-225g (females), 336.3 g (males)
- Housing: Before mating for all animals and after mating for males, the animals were housed no more than 5 of one sex to a cage in clear polysulfone cages measuring 59.5×38×20 cm (Tecniplast Gazzada S.a.r.l., Buguggiate, Varese). During the mating period, one male rat was housed with one female rat in clear polysulfone cages measuring 42.5×26.6×18.5 cm (Tecniplast Gazzada S.a.r.l., Buguggiate, Varese) with a
stainless steel mesh lid and floor. After mating, the mated females were housed individually in clear polysulfone cages measuring 42.5×26.6×18.5 cm (Tecniplast Gazzada S.a.r.l., Buguggiate, Varese). Nesting material was provided inside suitable bedding bags. Nesting material was changed at least 2 times a week
- Diet (e.g. ad libitum): drinking water, ad libitum
- Water (e.g. ad libitum): laboratory rodent diet (4 RF 21, Mucedola S.r.l., Via G. Galilei 4, 20019 Settimo Milanese (MI), Italy), ad libitum
- Acclimation period: 4 weeks
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22°C ± 2°C
- Humidity (%): 55% ± 15%
- Air changes (per hr): 15 to 20
- Photoperiod (hrs dark / hrs light): 12/12
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- CMC (carboxymethyl cellulose)
- Remarks:
- 0.5%
- Details on exposure:
- PREPARATION OF DOSING SOLUTION:
The required amount of test item was weighed and the required amount of vehicle was added. The mixture with a Silverson (medium head) was treated for 5 minutes and the resulting suspension was left under magnetic stirring for at least 3 hours prior to
dosing or analysis.
The formulation was prepared daily or up to a weekly interval (concentrations of 10, 30
and 100 mg/mL) according to the stability data. Concentrations were calculated and expressed in terms of test item as supplied. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Analysis was performed in a separate study in order to validate the analytical method and the formulation procedure and to verify the stability of the formulations. Samples of the formulations prepared during the current study (the first and the last week of treatment) were analysed to check the homogeneity and concentration. Chemical analysis was carried out by the Analytical Chemistry Department at ERBC. The software used for this activity was Empower® 2 Build No. 2154 (Waters).
Results of the analyses were within the acceptability limits stated in ERBC SOPs (85-115%
for concentration and CV < 10% for homogeneity). - Details on mating procedure:
- - Impregnation procedure: cohoused
- If cohoused: Females were paired one to one in the home cage of the male and left overnight.
- M/F ratio per cage: 1:1
- Length of cohabitation: over night
- Proof of pregnancy: sperm in the vaginal smear or the presence of a copulation plug, referred to as Day 0 of gestation. - Duration of treatment / exposure:
- GD6-19
- Frequency of treatment:
- once daily
- Duration of test:
- on GD 20, all surviving females were sacrificed
Doses / concentrations
- Remarks:
- Doses / Concentrations:
100, 300, 1000 mg/kg bw/day
Basis:
nominal conc.
- No. of animals per sex per dose:
- 25 mated females per group
- Control animals:
- yes
- Details on study design:
- - Dose levels were selected by the Sponsor.
- The oral route was selected as it is a possible route of exposure of the test item in man.
- The Wistar Hannover rat was the species and strain of choice because it is accepted by many regulatory authorities and there are ample experience and background data on this species and strain.
Examinations
- Maternal examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Mortality was checked early in each working day and again in the afternoon. At weekends and Public Holidays a similar procedure was followed except that the final check was carried out at approximately mid-day.
Clinical signs were recorded daily.
BODY WEIGHT: Yes
- Time schedule for examinations: on days 0, 3, 6, 9, 12, 15, 18 and 20 post coitum.
FOOD CONSUMPTION: Yes
- Time schedule for examinations: on days 3, 6, 9, 12, 15, 18 and 20 post coitum.
POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day 20
- Organs weight and fixated: Thyroid, Brain
- Histopathology: Thyroid
HORMONE ANALYSIS: Yes
- Time schedule: on Day 20 post coitum. - Ovaries and uterine content:
The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of late resorptions: Yes
- Other: number, sex and weight of all live foetuses, number and sex of dead foetuses (foetuses at term without spontaneous movements and breathing); number of intra-uterine deaths; gross evaluation of placentae.- Blood sampling:
- - Serum: Yes
- Volume collected: approximately 1 mL. The serum obtained was divided in two aliquots (300 µL in the aliquot A, the remaining in the aliquot B) - Fetal examinations:
- - Weight of each fetus: Yes
- Sex: Yes
- Gross evaluation of placentae: Yes
- External examinations: Yes: all per litter
- Soft tissue examinations: Yes: Approximately one-half of the foetuses
- Skeletal examinations: Yes: in the remaining foetuses
- Anogenital distance (AGD): Yes: each live foetus on Day 20 post cioitum - Statistics:
- For continuous variables the significance of the differences amongst group means was
assessed by Dunnett’s test or a modified t test, depending on the homogeneity of data.
Statistical analysis of non-continuous variables was carried out by means of the Kruskal-
Wallis test and intergroup differences between the control and treated groups assessed by a non-parametric version of the Williams test. - Indices:
- Pre-implantation loss % = no. of corpora lutea−no. of implantations/no. of corpora lutea x 100
Post-implantation loss % = no. of implantations−no. of live foetuses/ no. of implantations x 100
Total implantation loss % = no. of corpora lutea−no. of live foetuses/no. of corpora lutea x 100
Results and discussion
Results: maternal animals
General toxicity (maternal animals)
- Mortality:
- no mortality observed
- Description (incidence):
- All females survived to the final sacrifice on gestation Day 20.
Maternal developmental toxicity
- Details on maternal toxic effects:
- Maternal toxic effects: no effects
Details on maternal toxic effects:
- MORTALITY:
All females survived to the final sacrifice on gestation Day 20.
- CLINICAL SYMPTOMS:
No treatment-related clinical signs were recorded throughout the study. Signs of hairloss were observed in single animals regardless the treatment groups. Therefore, this sign was not attributed to treatment with the test item.
- FOOD CONSUMPTION:
Food consumption was comparable between treated and control groups throughout the study.
- BODY WEIGHT:
Maternal body weight and body weight gain were unaffected by treatment.
- TERMINAL BODY WEIGHT:
No test-substance related findings.
- UTERUS WEIGHT:
No test-substance related findings.
- HORMONE DETERMINATION:
Serum levels of T3, T4 and TSH did not differ between treated and control groups.
- NECROPSY FINDINGS:
Organ weights: There was no effect on terminal body weight or on the absolute and relative (to brain)
thyroid gland weights in treated females when compared to controls. Any organ weight variations were within the range of expected variations in Wistar rats of the same age and considered incidental and unrelated to treatment.
Macroscopic and microscopic observations: At post mortem examination, no treatment-related macroscopic observations were noted in treated females receiving test item up to 1000 mg/kg/day, when compared to controls. No treatment-related changes were noted in thyroid gland of females receiving the test item up to 1000 mg/kg/day, when compared to controls.
- REPRODUCTION DATA:
Two controls (nos. 3 and 19) and one low dose female (no. 63) were not pregnant. At necropsy, the uterus from one mid-dose female (no. 139) showed unilateral implantation (left horn) and the right one was not pregnant. The final number of females with live foetuses on gestation Day 20 was:
– 23 in the control group (0 mg/kg/day)
– 24 in the low dose group (100 mg/kg/day)
– 25 in the mid-dose group (300 mg/kg/day)
– 25 in the high dose group (1000 mg/kg/day)
Effect levels (maternal animals)
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- other: maternal toxicity
Maternal abnormalities
- Abnormalities:
- no effects observed
Results (fetuses)
- Details on embryotoxic / teratogenic effects:
- Embryotoxic / teratogenic effects:no effects
Details on embryotoxic / teratogenic effects:
- SEX DISTRIBUTION:
No treatment-related effects.
- WEIGHT OF FETUSES:
No treatment-related effects.
- ANOGENITAL DISTANCE:
The anogenital distance did not show differences between groups both in female and male foetuses.
- FETAL EXTERNAL EXAMINATIONS:
No abnormalities were recorded at external examination in all groups with exception of isolated cases of small foetuses (<2.7g) in treated groups.
- FETAL SKELETAL EXAMINATIONS:
The absence of one rib (13th) was noted in one low dose female. This major finding occurred as single case and it was considered incidental. Minor abnormalities or variations occurred in all groups and included for example altered ossification (asymmetrical, incomplete or no ossification) of several bones of the skull, sternebrae, thoracic/sacral vertebrae and the presence supernumerary ribs (14th). The incidence of the affected litters in treated groups was similar or even lower than observed in the control group or without dose relation. Therefore, the findings were considered unrelated to treatment.
- FETAL VISCERAL EXAMINATIONS:
No major abnormalities were found. The incidences of foetuses or litters with anomalies or variations did not suggest any test item effect.
Effect levels (fetuses)
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No adverse effects observed at highest tested dose
Fetal abnormalities
- Abnormalities:
- no effects observed
Overall developmental toxicity
- Developmental effects observed:
- no
Applicant's summary and conclusion
- Conclusions:
- Based on the results obtained in the study, the NOAEL (No Observed Adverse Effect Level) for maternal and developmental toxicity can be set at 1000 mg/kg/day.
- Executive summary:
In a GLP compliant prenatal developmental toxicity study (OECD 414), the test item (in 0.5%CMC) and administered by oral gavage at 100, 300 and 1000mg/kg/day to a total of 25 females per group. The animals were treated throughout the gestation period from Day 6 up to Day 19 post coitum. Control females received the vehicle (0.5 % CMC) at the same dose volume during the same treatment period.
No mortality occurred in the study. All females were sacrificed at termination and were pregnant with the exception of 2 controls and one female at 100 mg/kg/day. No treatment-related effects for observed for clinical signs, maternal body weight and body weight gain, food consumption, thyroid hormone determination, terminal body weight, uterus weight and absolute weigh gain, organ weight, litter data and sex ratio, anogenital distance and foetal examinations (macroscopic, microscopic, external, skeletal, visceral).
Based on the results obtained in the study, the NOAEL (No Observed Adverse Effect Level) for maternal and developmental toxicity can be set at 1000 mg/kg/day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.